GlassScriptPhysician profile
Sandra Gibiezaite
NPI 1255651873
$10,202.71
in general payments reported to CMS, 2019-2025
36 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $584 · 2021: $575 · 2022: $899 · 2023: $1,301 · 2024: $2,163 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,294 · Travel and Lodging: $583 · Education: $46.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,293.74 |
| Travel and Lodging | $583.13 |
| Education | $46.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,670.90 | 2019-2020 | |
| Medtronic, INC. | $1,564.22 | 2021-2025 | Minimed 780g, Solitaire X |
| Lilly USA, LLC | $1,159.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $700.89 | 2019-2025 | Omnipod, Omnipod |
| Amgen INC. | $594.56 | 2022-2025 | Evenity, Repatha, Tepezza |
| Abbott Laboratories | $583.20 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $531.95 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $522.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $455.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.15 | 2020-2023 | Jardiance |
| Ascendis Pharma Endocrinology INC | $236.77 | 2023-2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $200.27 | 2021-2025 | Unithroid |
| Corcept Therapeutics | $178.11 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $167.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $159.07 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $132.50 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $132.22 | 2021-2025 | |
| Dexcom, INC. | $124.85 | 2019-2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $99.95 | 2019 | |
| Glaxosmithkline, LLC. | $79.14 | 2022-2023 | Arexvy, Shingrix |
| Pfizer INC. | $66.50 | 2022-2024 | |
| Tolmar, INC. | $62.84 | 2024-2025 | Jatenzo |
| Horizon Therapeutics Plc | $54.77 | 2022-2023 | Tepezza |
| Radius Health, INC. | $51.40 | 2024-2025 | Tymlos |
| Kyowa Kirin, INC. | $51.37 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $47.00 | 2022-2024 | Strensiq |
| Neurocrine Biosciences, INC. | $33.42 | 2024-2025 | |
| Cequr Corporation | $30.00 | 2023 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $29.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Soleno Therapeutics, INC. | $26.39 | 2025 | Vykat Xr |
| Rhythm Pharmaceuticals, INC. | $21.89 | 2025 | Imcivree |
| Beta Bionics, INC. | $21.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Daiichi Sankyo INC. | $15.00 | 2021 | |
| Celgene Corporation | $14.96 | 2019 | |
| Ibsa Pharma INC. | $13.77 | 2023 | Tirosint, Licart |
| Ipsen Biopharmaceuticals, INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Gibiezaite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.